人工智能心电图用于恰加斯病机会性筛查:前瞻性可行性及诊断准确性评估
模型敏感度34.3%、特异度91.6%,AUC为77.6%,高于流行病学问卷模型和AI心电图模型,表明该模型可作为初级保健中可扩展的机会性筛查工具。
要点
- AI-ECG-EPI模型在流行区常规心电图中筛查恰加斯病,加权患病率12.2%。
- 模型敏感度34.3%、特异度91.6%,AUC 77.6%,区分能力优于问卷和AI心电图模型。
- 模型在女性和恰加斯心肌病患者中表现更高,支持其用于机会性筛查。
核心结论
- AI-ECG-EPI模型整合于公共远程心脏病学网络,在初级保健中实现可行的恰加斯病机会性筛查。
- 该模型诊断准确性可接受,区分能力高于流行病学问卷模型和AI心电图模型,并在流行区识别出许多既往未诊断患者。
研究设计与样本
- 前瞻性研究嵌入巴西米纳斯吉拉斯州远程医疗网络,覆盖107个高流行和流行市镇。
- 2023年10月至2024年9月,接受常规远程心电图的成人纳入;AI-ECG-EPI模型阳性者全部、阴性者按3:1抽样邀请血清学检测,采用逆概率加权分析。
主要发现
- 7804例被邀请血清学检测,3509例完成;阳性者中36.8%确诊恰加斯病,阴性者中9.3%确诊;加权患病率12.2%。
- 敏感度34.3%,特异度91.6%,精确率与召回率的调和平均分0.52,诊断比值比5.69。
- AI-ECG-EPI模型AUC为77.6%,高于流行病学问卷模型的70.0%和AI心电图模型的64.5%(P<0.001)。
- 探索性分析提示风险重分类改善,净重分类改善为0.503;模型在女性和恰加斯心肌病患者中表现更高。
关键数值与推荐
- AI-ECG-EPI模型敏感度34.3%、特异度91.6%、AUC 77.6%、诊断比值比5.69。
- 流行病学问卷模型AUC 70.0%,AI心电图模型AUC 64.5%,AI-ECG-EPI模型与之比较P<0.001。
- 加权恰加斯病患病率12.2%,筛查阳性率11.5%。
临床怎么用
- 可在流行区初级保健中利用常规远程心电图结合AI模型进行恰加斯病机会性筛查,阳性者进一步血清学确诊。
- 模型区分能力优于单纯问卷或AI心电图,有助于识别既往未诊断患者,支持可扩展筛查策略。
局限性
- 研究仅纳入巴西流行区成人,外推至非流行区或其他人群需谨慎。
- 血清学检测仅完成于部分受邀者,可能存在选择偏倚。
- 敏感度34.3%提示模型单独用于筛查可能漏诊较多病例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chagas disease (ChD), a neglected cardiovascular condition, affects 7.5 to 10.5 million people worldwide. Opportunistic screening during routine electrocardiography may allow earlier detection of unrecognized infections, enabling timely antiparasitic therapy or optimized cardiac care. This study prospectively evaluated the feasibility and diagnostic accuracy of an artificial intelligence (AI)-enabled ECG model enriched with 3 epidemiological questions (AI-ECG-EPI model) as an opportunistic screening for ChD in endemic regions of Brazil. METHODS: We conducted a prospective study embedded in the Telehealth Network of Minas Gerais, Brazil, across 107 municipalities in hyperendemic and endemic regions. From October 2023 to September 2024, adults undergoing routine tele-ECGs were eligible. The primary exposure was the output of the AI-ECG-EPI model: all positive individuals and a 3:1 sample of negative individuals were invited for serology (index test-dependent sampling), the reference standard. Weighted analyses (inverse probability) accounted for this sampling design. Diagnostic metrics included sensitivity, specificity, predictive values, likelihood ratios, area under the receiver operating characteristics curve, and area under the precision recall curve. The AI-ECG-EPI model was compared with both an epidemiological questions model and an AI ECG-only model. RESULTS: Among 75 779 eligible ECGs, the AI-ECG-EPI model was available for 59 154 individuals; 6812 (11.5%) screened positive. A total of 7804 selected were invited for serology, and 3509 completed testing (2517 positive; 992 negative). ChD was confirmed in 36.8% of positive and 9.3% of negative individuals. The weighted prevalence of ChD was 12.2%. Sensitivity was 34.3%, specificity 91.6%, harmonic mean of precision and recall score 0.52, and diagnostic odds ratio 5.69. The AI-ECG-EPI model showed higher discrimination than both the epidemiological questions model and AI ECG-only model (area under the receiver operating characteristics curve, 77.6% versus 70.0% and 64.5%, respectively; P<0.001). Precision recall curves showed higher precision across most recall levels. Exploratory analysis suggested improved risk reclassification (net reclassification improvement, 0.503). Performance was higher in women and in individuals with Chagas cardiomyopathy. CONCLUSIONS: In this community-based study, an AI-ECG-EPI model integrated into a public telecardiology network enabled feasible opportunistic screening for ChD in primary care. It showed acceptable diagnostic accuracy, with higher discrimination than epidemiological questions and AI ECG-only models, and identified many previously undiagnosed patients in endemic regions, supporting its potential role in scalable screening strategies. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02646943.
引用
- Ribeiro ALP, Cardoso CS, Taconeli CA, et al. Opportunistic Screening for Chagas Disease Using an Artificial Intelligence-Enabled ECG: Prospective Evaluation of Feasibility and Diagnostic Accuracy. Circulation. 2026. PMID: 42576808. doi:10.1161/CIRCULATIONAHA.125.078949
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。